Conference Call with Cipla Ltd. Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Cipla announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Income from Operations: Rs 6,730 crore compared to Rs 6,163 crore during Q4FY24, change 9.2%. EBITDA: Rs 1,538 crore compared to Rs 1,316 crore during Q4FY24, change 16.8%. EBITDA margin: 22.8% for Q4FY25. PAT: Rs 1,222 crore compared to Rs 939 crore during Q4FY24, change 30.1%. FY25 Financial Highlights: Income from Operations: Rs 27,548 crore compared to Rs 25,455 crore during FY24, change 8.2%. EBITDA: Rs 7,128 crore compared to Rs 6,233 crore during FY24, change 14.4%. EBITDA margin: 25.9% for FY25. PAT: Rs 5,273 crore compared to Rs 4,106 crore during FY24, change 28.4%. Umang Vohra MD and Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In FY25, we recorded a revenue growth of 8% over last year with the EBITDA margin of 25.9%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted an all-time high annual revenue of USD 934 million. In One Africa, we recorded a solid growth of 12% YoY in USD terms, powered by firm performance across key markets. Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”. Result PDF